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Abstract
Background: A disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) proteoglycanases are
specialized in the degradation of chondroitin sulfate proteoglycans and participate in mechanisms mediating
neuroplasticity. Despite the beneficial effect of ADAMTS-4 on neurorepair after spinal cord injury, the functions of
ADAMTS proteoglycanases in other CNS disease states have not been studied. Therefore, we investigated the
expression, effects and associated mechanisms of ADAMTS-4 during amyotrophic lateral sclerosis (ALS) in the
SOD1G93A mouse model.
Results: ADAMTS-4 expression and activity were reduced in the spinal cord of SOD1G93A mice at disease end-stage
when compared to WT littermates. To counteract the loss of ADAMTS-4, SOD1G93A and WT mice were treated with
saline or a recombinant ADAMTS-4 before symptom onset. Administration of ADAMTS-4 worsened the prognosis of
SOD1G93A mice by accelerating clinical signs of neuromuscular dysfunctions. The worsened prognosis of ADAMTS-4-
treated SOD1G93A mice was accompanied by increased degradation of perineuronal nets enwrapping motoneurons
and increased motoneuron degeneration in the lumbar spinal cord. Motoneurons of ADAMTS-4-treated SOD1G93A
mice were more vulnerable to degeneration most likely due to the loss of their extracellular matrix envelopes. The
decrease of neurotrophic factor production induced by ADAMTS-4 in vitro and in vivo may also contribute to a
hostile environment for motoneuron especially when devoid of a net.
Conclusions: This study suggests that the reduction of ADAMTS-4 activity during the progression of ALS pathology
may be an adaptive change to mitigate its neurodegenerative impact in CNS tissues. Therapies compensating the
compromized ADAMTS-4 activity are likely not promising approaches for treating ALS.
Keywords: A desintegrin and metalloproteinase with thrombospondin motifs, Amyotrophic lateral sclerosis,
Extracellular matrix, Neurodegeneration, Perineuronal net, Chondroitin sulfate proteoglycan, Astrogliosis, Nerve
growth factor, Brain-derived neurotrophic factor, Glial cell-derived neurotrophic factor
Background
A disintegrin and metalloproteinase with thrombospon-
din motifs type 4, ADAMTS-4, belongs to the subfamily
of ADAMTS proteases capable of degrading proteogly-
cans. The subfamily is composed of ADAMTS-1, −4, −5,
−8, −9, −15 and −20 [1, 2]. Increasing evidence suggests
that some ADAMTS proteoglycanases, for instance
ADAMTS-1 and −4, may play critical roles in the con-
trol of synaptic plasticity during CNS development and
aging via both protease-dependent and independent
mechanisms [2–4]. In addition, administration of
ADAMTS-4 has been recently described as a promising
therapeutic strategy to improve axonal regeneration/col-
lateral sprouting after spinal cord injury in rats by de-
grading chondroitin sulfate proteoglycans [5, 6]. While
deregulated expression of ADAMTS proteoglycanases
has been previously reported during acute CNS injuries,
such as stroke [7–9] and spinal cord injury [5, 6, 10], the
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expression and function of ADAMTS proteoglycanases
have not been studied in neurodegenerative diseases,
such as amyotrophic lateral sclerosis (ALS).
ALS is a devastating neurodegenerative disease char-
acterized by the selective death of upper and lower
motoneurons. Muscle wasting and weakness are early
signs of ALS, and finally, the patient’s death occurs
usually within 3–5 years after disease onset. In 90 % of
ALS cases, no apparent familial linkage has been iden-
tified, but in the remaining 10 % of the patients, the
disease is inherited [11]. Autosomal dominant muta-
tions in the Cu, Zn-superoxide dismutase (SOD1) gene
account for 20 % of the familial disease form [12, 13].
The two forms of ALS are clinically indistinguishable
and share many pathogenic features including oxida-
tive damage, mitochondrial dysfunction, endoplasmic
reticulum stress, excitotoxicity and inflammation [14].
Riluzole is the only FDA-approved drug for the treat-
ment of ALS but it unfortunately has a modest impact
of prolonging the life span of patients by only 2–3
months [15]. Therefore, it is essential to further
understand mechanisms underlying ALS development
in order to find new approaches for diagnostics and
therapy.
Considering the beneficial effect of ADAMTS-4 on
neuroplasticity, we aimed at investigating the expres-
sion, effects and associated mechanisms of ADAMTS-
4 in ALS. While the expressions of ADAMTS-1, −5
and −9 were increased in the lumbar spinal cord of
SOD1G93A mice compared to corresponding WT lit-
termates, the expression and activity of the most
expressed proteoglycanase, ADAMTS-4, were reduced
at the end-stage of the disease. To counteract the loss
of ADAMTS-4 expression in the spinal cord, recom-
binant ADAMTS-4 was administered to SOD1G93A
mice early prior to the onset of symptoms by intra-
cerebroventricular injections. Surprisingly, ADAMTS-
4 treatment promoted the degeneration of lumbar
spinal motoneurons by degrading their perineuronal
nets and led to a detrimental functional outcome in
SOD1G93A mice. Our results also show that
ADAMTS-4 decreased the synthesis and release of
neurotrophic factors by astrocytes and microglia in
vitro and in vivo.
While ADAMTS-4 has a beneficial impact on neuro-
plasticity and the subsequent functional outcome of in-
jured rats after spinal cord injury, it may represent a
damageable target in the context of ALS by accelerating
neurodegeneration and clinical signs of neuromuscular
dysfunctions in the SOD1G93A mouse model. The modu-
lation of the synthesis and release of neurotrophic fac-
tors by endogenous or exogenous ADAMTS-4 shows
that ADAMTS-4 functions are not limited solely to the
degradation of the extracellular matrix.
Results
ADAMTS-4 is the most expressed ADAMTS
proteoglycanase in the central nervous system
We first studied the differential expression of ADAMTS
proteoglycanases (ADAMTS-1, −4, −5, −9) in the lum-
bar spinal cord and in the cortex of adult WT mice by
RT-PCR. ADAMTS-4 was at least 8-fold more expressed
than the other ADAMTS proteoglycanases in the spinal
cord and in the cortex of WT mice (Fig. 1a: P = 0.0209
and P = 0.0495, respectively). Confocal imaging revealed
that the expression of ADAMTS-4 was widespread
within the spinal cord in the grey matter and also in the
white matter. Its expression was particularly abundant in
ventral horn neurons (Fig. 1b), astrocytes (Fig. 1c) and
oligodendrocytes (Fig. 1d). Negative controls with only
the secondary antibody used for ADAMTS-4 staining
failed to reveal any fluorescence (Fig. 1e).
Decrease of ADAMTS-4 activity in the lumbar spinal cord
of SOD1G93A mice at disease end-stage
We next studied the time course of the expression of
ADAMTS proteoglycanases (ADAMTS-1, −4, −5, −9)
in the lumbar spinal cord of SOD1G93A and age-
matched WT mice by RT-PCR at key time points of
ALS progression (eg. presymptomatic (PS), symptom-
atic (SS) and end (ES) stages). ADAMTS-4 mRNA
levels were considerably decreased in SOD1G93A male
mice compared to WT at the symptomatic and end-
stages of the disease (Fig. 2a: −53.7 % at SS, −85.7 % at
ES compared to age-matched WT, P = 0.0209). Contrary to
ADAMTS-4, ADAMTS-1 (Fig. 2b: +92.1 % at SS,
+410.7 % at ES compared to age-matched WT, P =
0.0433, P = 0.0209, respectively), ADAMTS-5 (Fig. 2c:
+148.9 % at ES compared to age-matched WT, P =
0.0339) and ADAMTS-9 (Fig. 2d: +149.6 % at ES com-
pared to age-matched WT, P = 0.0209) mRNA levels
were significantly increased in the lumbar spinal cord
of SOD1G93A male mice compared to WT at the symp-
tomatic and/or end-stages of the disease. Similarly,
ADAMTS-4 mRNA levels were considerably de-
creased in the lumbar spinal cord of SOD1G93A female
mice compared to WT at all the stages of the disease
(Fig. 2e: −38.9 % at PS, −48.9 % at SS, −82.7 % at ES
compared to age-matched WT, P = 0.0339, P = 0.0209,
P = 0.0339, respectively). Conversely, ADAMTS-1
(Fig. 2f: +60.5 % at SS, +472 % at ES compared to age-
matched WT, P = 0.0209, P = 0.0339, respectively),
ADAMTS-5 (Fig. 2g: +33.6 % at SS, +171 % at ES com-
pared to age-matched WT, P = 0.0209, P = 0.0339, respect-
ively) and ADAMTS-9 (Fig. 2h: +35.8 % at SS, +114,9 % at
ES compared to age-matched WT, P = 0.0209, P = 0.0339,
respectively) mRNA levels were significantly increased in
the lumbar spinal cord of SOD1G93A female mice compared
to WT at the symptomatic and end-stages of the disease.
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Confocal imaging revealed an abundant expression of
ADAMTS-4 in ventral horn neurons of WT mice (Fig. 1b),
and a loss/degeneration of motoneurons occurring at dis-
ease end-stage in SOD1G93A mice (Fig. 2i).
No modifications of ADAMTS-4 protein levels were ob-
served between WT and SOD1G93A male mice at the pre-
symptomatic and symptomatic stages (Fig. 2j-k: P = 0.1482
and P = 0.5637, respectively). However, at the end-stage of
the disease, the decrease of ADAMTS-4 mRNA levels in
the lumbar spinal cord of SOD1G93A male mice was accom-
panied by a decrease of the protein levels of the mature
form of ADAMTS-4 (p68) (Fig. 2l: −50.1 % at ES compared
to age-matched WT, P = 0.0209) and an increase of its
truncated form (p53) (Fig. 2l: +898.5 % at ES compared to
age-matched WT, P = 0.0209). As previously observed for
SOD1G93A male mice, no modifications of ADAMTS-4
protein levels were observed between WT and SOD1G93A
female mice at the presymptomatic and symptomatic stages
(Fig. 2m-n: P = 0.5637 and P = 0.2482, respectively), but at
the end-stage of the disease, the decrease of ADAMTS-4
mRNA levels in the lumbar spinal cord of SOD1G93A
female mice was accompanied by a decrease of the
protein levels of the mature form of ADAMTS-4 (p68)
(Fig. 2o: −52.4 % at ES compared to age-matched WT,
P = 0.0143) and an increase of its truncated form (p53)
(Fig. 2o: +218 % at ES compared to age-matched WT,
Fig. 1 ADAMTS-4 expression in the central nervous system. a Differential mRNA expression of ADAMTS proteoglycanases (eg. ADAMTS-1, −4, −5
and −9) in the lumbar spinal cord (SC) and in the cortex of 3-month-old WT male (♂) and female (♀) mice. Ct values are indicated in the histograms.
Values plotted are mean ± SEM. Mann–Whitney U-tests: *P < 0.05 compared to ADAMTS-1 expression, $P < 0.05 compared to ADAMTS-4
expression, #P < 0.05 compared to ADAMTS-5 expression, N = 3-4. b-d Representative photomicrographs of lumbar spinal cord sections
from WT mice stained with: ADAMTS-4 (green) and NeuN (neuronal marker, red) (b) ADAMTS-4 (green) and GFAP (astrocyte marker, red)
(c) or ADAMTS-4 (green) and APC (oligodendrocyte marker, red) (d). Corresponding Alexa fluor-488 negative controls for ADAMTS-4 (green)
in the grey and white matter are shown in e
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Fig. 2 (See legend on next page.)
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P = 0.0209). No significant modifications of ADAMTS-
4 truncated form (p40) were observed (Figs. 2l, o:
quantifications not shown).
Then, quantitative RT-PCR was performed for the
mRNA expression of the most potent inhibitor of
ADAMTS-4, TIMP-3 (type 3 tissue inhibitor of metallo-
proteinases) [16], in the lumbar spinal cord of WT and
SOD1G93A male and female mice at the different stages
of the disease. TIMP-3 mRNA levels were found to be
increased in the lumbar spinal cord of SOD1G93A male
mice compared to WT at the symptomatic and end-stages
of the disease (Fig. 2p: +38.3 % at SS, +70.8 % at ES
compared to age-matched WT, P = 0.0339, P = 0.0209, re-
spectively). For female mice, TIMP-3 mRNA levels were
also increased in the lumbar spinal cord of SOD1G93A mice
compared to WT at the presymptomatic and end-stages of
the disease (Fig. 2q: +59.6 % at PS, +138.8 % at ES com-
pared to age-matched WT, P = 0.0339).
Consequently, the enzymatic activity of ADAMTS-4
was reduced in the lumbar spinal cord of SOD1G93A
male (Fig. 2r: −35.8 % at ES compared to age-matched
WT, P = 0.0209) and female (Fig. 2s: −25.9 % at ES com-
pared to age-matched WT, P = 0.0209) mice at disease
end-stage
To further examine whether the loss of ADAMTS-4
at disease end-stage was specific to the lumbar spinal
cord, we studied the expression of ADAMTS-4 in the
cervical and thoracic parts of the spinal cord, as well as
in the cortex, of WT and SOD1G93A mice by western
blot. Interestingly, there was a decrease of ADAMTS-4
expression in the cervical and thoracic spinal cord of
SOD1G93A male mice compared to WT (Fig. 3a-b: −65.5 %
in the cervical (A) and −38.2 % in the thoracic (B) spinal
cord at ES compared to age-matched WT, P = 0.0209), but
no significant modification of ADAMTS-4 expression in
the cortex was observed (Fig. 3c: P = 0.1489). For females,
no modification of ADAMTS-4 expression was observed in
the cervical spinal cord of SOD1G93A mice compared to
WT (Fig. 3d: P = 0.1489), but we observed a significant de-
crease of ADAMTS-4 expression in the thoracic spinal
(See figure on previous page.)
Fig. 2 Decrease of ADAMTS-4 activity in the lumbar spinal cord of SOD1G93A mice at disease end-stage. a-h Quantitative RT-PCR for ADAMTS-4
(a, e) ADAMTS-1 (b, f) −5 (c, g) and −9 (d, h) expression in the lumbar spinal cord (SC) of WT (blank bar) and SOD1G93A (black bar) male (♂; a, b,
c, d) or female (♀; e, f, g, h) mice at presymptomatic (PS), symptomatic (SS) and end (ES) stages. Values plotted are mean ± SEM. Mann–Whitney
U-tests: *P < 0.05 compared to corresponding WT mice, $P < 0.05 compared to SOD1G93A mice at other stages, #P < 0.05 compared to WT mice at
other stages, N= 3-4. i Representative photomicrographs of ventral horns in lumbar spinal cord sections from WT and SOD1G93A mice at end-stage stained
with ADAMTS-4 (green) and NeuN (neuronal marker, red). Scale bar = 20 μm. j-o Immunoblot for ADAMTS-4 in the lumbar spinal cord of
WT and SOD1G93A male (j-l) and female (m-o) mice at PS, SS and ES. The immunoblots revealed ADAMTS-4 mature form (p68), ADAMTS-4
truncated forms (p53, p40) and a 16 kDa fragment. Values plotted are mean ± SEM. Mann–Whitney U-tests: *P < 0.05 compared to corresponding WT mice,
N= 4-5. p-q Quantitative RT-PCR for TIMP-3 in the lumbar spinal cord of WT and SOD1G93A male (p) and female (q) mice at PS, SS and ES. Values plotted
are mean ± SEM. Mann–Whitney U-tests: *P < 0.05 compared to corresponding WT mice, $P < 0.05 compared to SOD1G93A mice at other stages, #P < 0.05
compared to WT mice at other stages, N= 3-4. r-s ADAMTS-4 enzymatic activity assay in the lumbar spinal cord of WT and SOD1G93A male (r) and female
(s) mice at PS, SS and ES. Values plotted are mean ± SEM. Mann–Whitney U-tests: *P < 0.05 compared to corresponding WT mice, $P < 0.05 compared to
SOD1G93A mice at other stages, #P < 0.05 compared to WT mice at other stages, N= 4
Fig. 3 Spinal cord-specific decrease of ADAMTS-4 expression in
SOD1G93A mice at disease end-stage. a-f Immunoblot for ADAMTS-4
in the cervical or thoracic spinal cord (SC) and in the cortex of WT
(blank bar) and SOD1G93A (black bar) male (♂; a, b, c) or female
(♀; d, e, f) mice at disease end-stage (ES). Values plotted are mean ±
SEM. Mann–Whitney U-tests: *P < 0.05 compared to corresponding WT
mice, N= 4
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cord of SOD1G93A mice compared to WT (Fig. 3e: −66.3 %
in the thoracic spinal cord at ES compared to age-matched
WT, P = 0.0209). Again, no modification of ADAMTS-4 ex-
pression was observed in the cortex (Fig. 3f: P = 0.2207).
No significant modifications of ADAMTS-4 truncated
forms (p53 and p40) were observed (Figs. 3a-f; quantifica-
tions not shown). We also observed the appearance of a
16 kDa fragment in protein extracts of both spinal cords
and cortices of SOD1G93A mice at all the stages of the dis-
ease, even when the mature form of ADAMTS-4 (p68) was
unchanged when compared to corresponding WT mice
(Fig. 2j-o, Fig. 3a-f).
Then, we studied the expression of ADAMTS-5 in the
lumbar spinal cord of WT and SOD1G93A mice by west-
ern blot. Surprisingly, while the mRNA levels of
ADAMTS-5 were increased in the lumbar spinal cord at
the end-stage in SOD1G93A male mice and at the symp-
tomatic and end-stages in SOD1G93A female mice, no
modifications were found at the protein levels between
WT and SOD1G93A mice at any stage of the disease
(Fig. 4a-c: P = 0.0833, P = 0.3865, P = 0.2482 at PS, SS
and ES respectively compared to age-matched male WT;
Fig. 4d-f: P = 0.5637, P = 0.2482, P = 0.5637 at PS, SS and
ES respectively compared to age-matched female WT).
To summarize, the expression and the synthesis of
ADAMTS-4 and its inhibitor TIMP-3, as well as
ADAMTS-4 proteolytic cleavage profile, were considerably
altered in the spinal cord of SOD1G93A mice at the end-
stage of the disease, representing a series of events leading
to the decrease of ADAMTS-4 enzymatic activity.
Presymptomatic treatment with recombinant ADAMTS-4
worsens the prognosis of SOD1G93A mice
To prevent the loss of ADAMTS-4 activity at disease
end-stage, a human recombinant ADAMTS-4 previously
shown to be biologically active and to support neuro-
plasticity [5] was administered to SOD1G93A mice early
before the onset of symptoms by intracerebroventricular
Fig. 4 No modification of ADAMTS-5 expression in the lumbar spinal cord of SOD1G93A mice at any stage of the disease. a-f Immunoblot for
ADAMTS-5 (73 kDa) in the lumbar spinal cord of WT and SOD1G93A male (a-c) and female (d-f) mice at PS, SS and ES. Values plotted are mean ±
SEM. Mann–Whitney U-tests: P > 0.05 compared to corresponding WT mice, N = 4
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injections. Control SOD1G93A mice were injected with
saline in the same conditions. Age-matched WT mice
were also treated with saline or ADAMTS-4. The onset
of symptoms was determined by the appearance of clin-
ical signs of neuromuscular dysfunction, measured by
the loss of ability for SOD1G93A mice to hold onto an
inverted lid. ADAMTS-4 treatment was detrimental in
SOD1G93A male mice by bringing forward the probabil-
ity of onset of symptoms compared to saline-treated
SOD1G93A male mice (Fig. 5a: median asymptomatic
survival: 189 d for control and 174 d for ADAMTS-4
SOD1G93A, P = 0.0488). Accordingly, there was a signifi-
cant decrease of the age at symptom onset in
ADAMTS-4-treated SOD1G93A male mice (Fig. 5b: aver-
age age of onset: 197.8 ± 8.5 d for control and 176.2 ± 3.9
d for ADAMTS-4 SOD1G93A, P = 0.0423). No change in
the latency to fall was observed during the first week fol-
lowing the symptom onset between ADAMTS-4-treated
and saline-treated SOD1G93A male mice (Fig. 5c: time la-
tency to fall: 156.7 ± 14.0 s for control and 160.4 ± 5.2 s
for ADAMTS-4 SOD1G93A, P = 0.7573). Surprisingly,
ADAMTS-4 treatment did not affect the probability of
symptom onset (Fig. 5d: median asymptomatic survival:
241 d for control and 240.5 d for ADAMTS-4
SOD1G93A, P = 0.4787) or the age at symptom onset in
ADAMTS-4-treated SOD1G93A female mice compared
to untreated mice (Fig. 5e: average age of onset: 236.0 ±
5.0 d for control and 240.3 ± 6.2 d for ADAMTS-4
SOD1G93A, P = 0.3798). However, the latency to fall dur-
ing the first week following the symptom onset was sig-
nificantly reduced in ADAMTS-4-treated SOD1G93A
female mice compared to untreated mice (Fig. 5f: time
latency to fall: 157.6 ± 5.3 s for control and 107.8 ± 18.5 s
for ADAMTS-4 SOD1G93A, P = 0.0455). Failure to gain
body weight is another indicator of disease onset and
progression in SOD1G93A mice, therefore the weight of
WT and SOD1G93A mice was recorded from 150 to
190 days for males (Fig. 5g) and from 200 to 240 days
for females (Fig. 5h). While no genotype effect was evi-
dent in male mice at any time point, there was a geno-
type effect in female mice. Contrary to WT female mice,
the SOD1G93A female mice failed to gain weight over
time. We did not observe any change in the weight of
ADAMTS-4-treated WT mice (Figs. 5g-h: P > 0.05).
Overall, our data show that preventing the loss of en-
dogenous ADAMTS-4 activity by exogenous provision
of an active human recombinant protein is detrimental
for functional outcome in the context of ALS.
ADAMTS-4 treatment accelerates neurodegeneration in
the ventral horn of the lumbar spinal cord in SOD1G93A
mice
Motoneuron survival in the ventral horn of lumbar
spinal cord of WT and SOD1G93A mice was quantified
to determine whether the decline of motor function in
ADAMTS-4-treated SOD1G93A mice was a result of ac-
celerated spinal cord pathology. In SOD1G93A mice,
there was an approximately 50 % loss of motoneurons
compared to age-matched WT mice (Fig. 6: P < 0.001).
ADAMTS-4 did not affect the severity of motoneuron
loss in SOD1G93A male mice (Fig. 6a, b: P = 0.8297).
However, the size of the remaining motoneurons was
significantly smaller in ADAMTS-4-treated SOD1G93A-
mice (Fig. 6a, c: −13.8 % for ADAMTS-4-treated SOD1G93A
mice compared to untreated SOD1G93A mice, P = 0.0496).
On the contrary, the number of motoneurons was de-
creased by approximately 2-fold in ADAMTS-4-treated
SOD1G93A female mice compared to untreated SOD1G93A
female mice (Fig. 6d, e: −55.7 % for ADAMTS-4-treated
SOD1G93A mice compared to untreated SOD1G93A
mice, P = 0.0347). However, the size of the remaining
motoneurons was not different from those of un-
treated SOD1G93A female mice (Fig. 6d, f: P = 0.6961).
ADAMTS-4 treatment had no effect on motoneurons
in WT mice. Overall, the results demonstrate that
ADAMTS-4 promotes neurodegeneration in ALS
pathology.
ADAMTS-4 treatment reduces perineuronal nets
enwrapping motoneurons in the ventral horn of the
lumbar spinal cord in SOD1G93A mice
To further understand how ADAMTS-4 promotes degen-
eration/cell death of motoneurons, we then quantified peri-
neuronal nets (PNNs) enwrapping motoneurons, which are
protective extracellular matrix (ECM)-envelopes containing
chondroitin sulfate proteoglycans (CSPGs), well-known
substrates for ADAMTS-4 [17]. For this purpose, lumbar
spinal cord sections of SOD1G93A and age-matched WT
mice treated or not with ADAMTS-4 were stained with
Wisteria Floribunda Agglutin (WFA), a common marker
for PNNs [18, 19]. In SOD1G93A mice, there was an
approximately 70 % loss of PNNs compared to age-
matched WT mice at symptomatic stage (Fig. 7: P < 0.001).
The amount of the remaining PNNs was even smaller in
ADAMTS-4-treated SOD1G93A male (Fig. 7a-b: −69.4 % for
ADAMTS-4-treated SOD1G93A mice compared to un-
treated SOD1G93A mice, P = 0.0040) and female
(Fig. 7c-d: −74 % for ADAMTS-4-treated SOD1G93A mice
compared to untreated SOD1G93A mice, P = 0.0210) mice.
Additionally, the amount of PNNs was positively correlated
with the number of motoneurons in the ventral horn of the
spinal cords (Fig. 7e: P = 0.0002, R = 0.5474). Again,
ADAMTS-4 treatment had no effect on PNNs of WT mice.
To determine why the PNNs of SOD1G93A mice were sen-
sitive to ADAMTS-4 treatment while PNNs of WT mice
were not, RT-qPCR were carried out for the expression of
several PNN components in the lumbar spinal cord of WT
and SOD1G93A mice: aggrecan (a CSPG present exclusively
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in PNNs), HPLAN1 (hyaluronan and proteoglycan link
protein 1; involved in the interaction between hyaluronan
and CSPGs) and tenascin R (involved in the interaction be-
tween the cell surface and CSPGs). Importantly, we ob-
served a decrease of aggrecan expression in the lumbar
spinal cord of SOD1G93A male mice compared to WT
at the presymptomatic and end-stages of the disease
(Fig. 7f: −20.5 % at PS, −30 % at ES compared to age-
matched WT, P = 0.0339). For female mice, aggrecan
mRNA levels were also decreased in the lumbar spinal cord
Fig. 5 Presymptomatic treatment with rADAMTS-4 worsens the prognosis of SOD1G93A mice. a Kaplan-Meier graph showing the probability of
symptom onset in SOD1G93A males treated with saline (Control; black line) or recombinant ADAMTS-4 (ADAMTS-4; gray line) at early presymptomatic stage.
Log-rank (Mantel-Cox) Test: *P < 0.05 compared to the control group, N= 9. b Mean age at onset of mice from panel a. Values plotted are mean ± SEM.
Mann–Whitney U-test: *P < 0.05 compared to the control group, N= 9. c The best wire hang performance during the first week after symptom onset.
Values plotted are mean ± SEM. Mann–Whitney U-test: P > 0.05 compared to the control group, N= 9. d Kaplan-Meier graph showing the probability of
symptom onset in SOD1G93A females treated with saline (Control; black line) or recombinant ADAMTS-4 (ADAMTS-4; gray line) during early presymptomatic
stage. Log-rank (Mantel-Cox) Test: P > 0.05 compared to the control group, N= 7 Control SOD1G93A, N= 6 ADAMTS-4 SOD1G93A. e Mean age at onset of
mice from panel D. Values plotted are mean ± SEM. Mann–Whitney U-test: P > 0.05 compared to the control group, N= 7 Control SOD1G93A, N= 6
ADAMTS-4 SOD1G93A. f The best wire hang performance during the first week after symptom onset. Values plotted are mean ± SEM. Mann–Whitney U-test:
*P < 0.05 compared to the control group, N= 7 Control SOD1G93A, N= 6 ADAMTS-4 SOD1G93A. g-h Weight over time of WT and SOD1G93A male (g) or
female (h) mice treated or not with saline or recombinant ADAMTS-4 during early presymptomatic stage. Values plotted are mean ± SEM. Two-way Anova:
**P < 0.01, ***P < 0.001 WT Vs SOD1G93A, N= 5 Control WT males, N= 5 ADAMTS-4 WT males, N= 9 Control SOD1G93A males, N= 9 ADAMTS-4 SOD1G93A
males, N= 5 Control WT females, N= 4 ADAMTS-4 WT females, N= 7 Control SOD1G93A females, N= 6 ADAMTS-4 SOD1G93A females
Lemarchant et al. Molecular Neurodegeneration  (2016) 11:10 Page 8 of 24
of SOD1G93A mice compared to WTat the end-stage of the
disease (Fig. 7g: −34 % at ES compared to age-matched
WT, P = 0.0339). Then, we observed a decrease of HAPLN1
expression in the lumbar spinal cord of SOD1G93A male
mice compared to WT at the presymptomatic and end-
stages of the disease (Fig. 7h: −30.7 % at PS, −42.7 % at ES
compared to age-matched WT, P = 0.0339). For female
mice, HAPLN1 mRNA levels were also decreased in the
lumbar spinal cord of SOD1G93A mice compared to WT at
the end-stage of the disease (Fig. 7i: −48.1 % at ES com-
pared to age-matched WT, P = 0.0339). Finally, we observed
an increase of tenascin R expression in the lumbar spinal
cord of SOD1G93A male and female mice compared to
WT at the symptomatic and end-stages of the disease
(Fig. 7j: +33.6 % at SS, +74.3 % at ES compared to age-
matched male WT, P = 0.0339; Fig. 7k: +25.3 % at SS,
+47.7 % at ES compared to age-matched female WT,
P = 0.0433 and 0.0339 respectively). To determine
whether the degradation of CSPG core protein present
in PNNs was specific of ADAMTS-4 recombinant pro-
tein, we exposed or not lumbar spinal cord protein ex-
tracts from SOD1G93A male mice at symptomatic stage
to human recombinant ADAMTS-1, ADAMTS-4 or
ADAMTS-5 ex vivo for 24 h at 37 °C. Interestingly, we
evidenced that only ADAMTS-4 recombinant protein
was successful to degrade CSPG core proteins ex vivo
(Fig. 7l: −53 % of CSPG core proteins in ADAMTS-4-
incubated protein extracts compared to the control
condition, P = 0.0209; P > 0.05 between ADAMTS-1 or
ADAMTS-5-incubated protein extracts and the con-
trol condition).
ADAMTS-4 treatment increases astrogliosis in the ventral
horn of the lumbar spinal cord of female SOD1G93A mice
Astrogliosis and microgliosis are classical hallmarks of ALS
pathology and strongly contribute to neurodegeneration.
Fig. 6 rADAMTS-4 accelerates neurodegeneration in the lumbar
spinal cord of SOD1G93A mice. a Representative photomicrographs
of ventral horns in lumbar spinal cord sections from WT and control
or ADAMTS-4-treated SOD1G93A male mice stained with ChAT. Scale
bar: 500 or 250 μm. b-c Quantification of average spinal motoneuron
number (b) and size (c) in male mice from (a). Values plotted are
mean ± SEM. Two-way ANOVA: ***P < 0.001 WT Vs SOD1G93A. Unpaired
two-tailed t-Test: P > 0.05 (Number) or $P < 0.05 (Size) Control Vs
ADAMTS-4 SOD1G93A, N = 3 Control WT, N = 5 ADAMTS-4 WT, N = 8
Control SOD1G93A, N = 7 ADAMTS-4 SOD1G93A. d Representative
photomicrographs of ventral horns in lumbar spinal cord sections
from WT and control or ADAMTS-4-treated SOD1G93A female mice
stained with ChAT. Scale bar: 500 or 250 μm. e-f Quantification of
average spinal motoneuron number (e) and size (f) in female
mice from (d). Values plotted are mean ± SEM. Two-way ANOVA:
***P < 0.001 WT Vs SOD1G93A. Unpaired two-tailed t-Test: $P < 0.05
(Number) or P > 0.05 (Size) Control Vs ADAMTS-4 SOD1G93A, N = 5
Control WT, N = 3 ADAMTS-4 WT, N = 5 Control SOD1G93A, N = 6
ADAMTS-4 SOD1G93A
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Therefore, we next investigated whether ADAMTS-4 in-
creases gliosis in the ventral horn of the lumbar spinal cord
of SOD1G93A compared to untreated SOD1G93A mice. In
SOD1G93A mice, there was a remarkable increase of the
astrocyte marker, GFAP (glial fibrillary acidic protein), com-
pared to age-matched WT mice (Fig. 8a-c: P < 0.001).
While no modification of GFAP expression was observed
in ADAMTS-4-treated SOD1G93A male mice compared to
untreated SOD1G93A male mice (Fig. 8b: P = 0.8514),
ADAMTS-4 significantly increased GFAP immunore-
activity in SOD1G93A female mice (Fig. 8c: +126.7 %
for ADAMTS-4-treated SOD1G93A mice compared to
untreated SOD1G93A mice, P = 0.0414). In SOD1G93A
mice, there was an approximately 10-fold increase of
the microglial marker, Iba1 (ionized calcium-binding
adapter molecule-1), compared to age-matched WT
mice (Fig. 8d-f: P < 0.001). No change in Iba1 expres-
sion was observed in ADAMTS-4-treated SOD1G93A mice
compared to untreated SOD1G93A mice (Fig. 8e-f:
P = 0.1146 for males and P = 0.5893 for females).
GFAP and Iba1 immunoreactivities in WT mice were not
altered by ADAMTS-4 treatment.
ADAMTS-4 treatment does not directly affect neuronal
survival in vitro
Glutamate-induced excitotoxicity represents a key
pathophysiological process in ALS contributing to neu-
rodegeneration through activation of Ca2+-dependent
enzymatic pathways [14]. We therefore aimed at deter-
mining whether ADAMTS-4 directly influenced neur-
onal death in vitro using cortical neurons exposed or not
to glutamate for 24 h. Exogenous ADAMTS-4 was not
toxic to neurons in control conditions (Fig. 9a: P = 0.4158).
When neurons were exposed to glutamate, the amount
of viable cells was decreased by about 40 % (Fig. 9b, d:
P < 0.0001). However, ADAMTS-4 did not promote
glutamate-induced toxicity (Fig. 9b: P = 0.3559, P = 0.1962,
P = 0.2505, P = 0.2423 for cell viability when neurons were
exposed to glutamate compared to glutamate in presence
of ADAMTS-4 at 20, 100, 200, 500 ng/ml respectively).
Similarly, we did not observe any influence of exogenous
ADAMTS-1 on neuronal viability in control conditions
(Fig. 9c: P = 0.5896) or after glutamate exposure (Fig. 9d:
P > 0.9999, P = 0.7782, P = 0.8880, P = 0.5732 for cell viabil-
ity when neurons were exposed to glutamate compared to
glutamate in presence of ADAMTS-1 at 20, 100, 200,
500 ng/ml respectively).
Exogenous and endogenous ADAMTS-4 modulate the
expression and release of neurotrophic factors by glial
cells in vitro
Since ADAMTS-4 did not influence directly neuronal
survival in vitro (Fig. 9), we aimed at investigating sec-
ondary pathways through which ADAMTS-4 may confer
the neurodegeneration/death observed in vivo (Fig. 6).
For that purpose, we investigated whether ADAMTS-4
may modulate the expression and/or release of neuro-
trophic factors such as NGF (nerve growth factor),
GDNF (glial cell-derived neurotrophic factor) and BDNF
(brain-derived neurotrophic factor), in astrocyte and
microglia cultures. ADAMTS-4 was found to decrease
the mRNA levels of NGF (Fig. 10a: −30.2 % or −28.1 %
for astrocytes treated with ADAMTS-4 at 20 or 100 ng/
ml compared to control astrocytes, P = 0.0209), GDNF
(Fig. 10b: −11.9 % for astrocytes treated with ADAMTS-
4 at 200 ng/ml compared to control astrocytes, P = 0.0209)
and BDNF (Fig. 10c: −25.2 %, −25.6 % or −14.9 % for astro-
cytes treated with ADAMTS-4 at 20, 100 or 200 ng/ml
compared to control astrocytes, P = 0.0209) in astrocytes.
The reduction of NGF mRNA levels by ADAMTS-4
(Fig. 10a) was accompanied by a decrease of NGF present
in the culture media (Fig. 10d: −15.9 % or −23.1 % for as-
trocytes treated with ADAMTS-4 at 20 or 100 ng/ml com-
pared to control astrocytes, P = 0.0495). This effect was
specific to ADAMTS-4, since a human recombinant
ADAMTS-1 did not change the levels of NGF present in
(See figure on previous page.)
Fig. 7 rADAMTS-4 reduces perineuronal nets enwrapping motoneurons in the lumbar spinal cord of SOD1G93A mice. a Representative
photomicrographs of ventral horns in lumbar spinal cord sections from WT and control or ADAMTS-4-treated SOD1G93A male mice stained with
WFA, a marker of perineuronal nets. Scale bar: 500 or 250 μm. b Quantification of WFA immunoreactivity per area from male mice (a). Values
plotted are mean ± SEM. Two-way ANOVA: ***P < 0.001 WT Vs SOD1G93A. Unpaired two-tailed t-Test: $$P < 0.01 Control Vs ADAMTS-4 SOD1G93A, N
= 3 Control WT, N = 5 ADAMTS-4 WT, N = 8 Control SOD1G93A, N = 7 ADAMTS-4 SOD1G93A. c Representative photomicrographs of ventral horns in
lumbar spinal cord sections from WT and control or ADAMTS-4-treated SOD1G93A female mice stained with WFA. Scale bar: 500 or 250 μm. d
Quantification of WFA immunoreactivity per area from female mice (c). Values plotted are mean ± SEM. Two-way ANOVA: ***P < 0.001 WT Vs
SOD1G93A. Unpaired two-tailed t-Test: $P < 0.05 Control Vs ADAMTS-4 SOD1G93A, N= 5 Control WT, N= 3 ADAMTS-4 WT, N= 5 Control SOD1G93A, N= 6
ADAMTS-4 SOD1G93A. e Positive correlation between the percentage of WFA-positive perineuronal nets per area and the number of motoneurons in male
and female WT (N= 15; blank diamond) and SOD1G93A (N= 24; black diamond) symptomatic mice from figs. 4–5. Spearman’s rank correlation: ***P < 0.001.
R represents the coefficient of correlation. f-k Quantitative RT-PCR for aggrecan (f-g) HAPLN1 (h-i) and tenascin R (j-k) in the lumbar spinal
cord of WT and SOD1G93A male (f, h, j) and female (g, i, k) mice at PS, SS and ES. Values plotted are mean ± SEM. Mann–Whitney U-tests:
*P < 0.05 compared to corresponding WT mice, $P < 0.05 compared to SOD1G93A mice at other stages, #P < 0.05 compared to WT mice at
other stages, N = 3-4. l Immunoblot for CSPG (chondroitin sulfate proteoglycans) core proteins in lumbar spinal cord protein extracts of
SOD1G93A mice exposed to human recombinant ADAMTS-1, ADAMTS-4 or ADAMTS-5 ex vivo for 24 h at 37 °C. Quantification of total CSPG
core proteins. Values plotted are mean ± SEM. Mann–Whitney U-tests: *P < 0.05 between control and ADAMTS-4 conditions, N = 4
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the culture media (Fig. 10e: P = 0.5127). ADAMTS-4 was
not toxic to cultured astrocytes.
To confirm these results, we transfected astrocytes for
2 h with silencing siRNAs targeting ADAMTS-4 or with
an empty vector (mock) as a control. After 48 h,
ADAMTS-4 gene expression was decreased by 69 % in
astrocytes transfected with siRNAs silencing ADAMTS-
4 expression compared to control astrocytes (Fig. 10f:
P = 0.0209). Interestingly, we observed an increase of
the mRNA levels of NGF (Fig. 10g: +46.1 % for astro-
cytes transfected with siRNAs targeting ADAMTS-4
compared to control astrocytes, P = 0.0209) and GDNF
(Fig. 10h: +46.8 % for astrocytes transfected with siR-
NAs targeting ADAMTS-4 compared to control astro-
cytes, P = 0.0209), but not BDNF (Fig. 10i: P = 0.2482),
in astrocytes transfected with siRNAs silencing
ADAMTS-4 expression compared to control astro-
cytes. In the culture media, we observed an increase of
NGF in astrocytes transfected with siRNAs silencing
ADAMTS-4 expression compared to control astro-
cytes (Fig. 10j: +16.9 % for astrocytes transfected with
siRNAs targeting ADAMTS-4 compared to control as-
trocytes, P = 0.0209).
To determine whether this effect was astrocyte-
specific, we repeated the same experiments in microglia
cultures. ADAMTS-4 decreased the mRNA levels of
NGF (Fig. 10k: −9.4 % for microglia treated with
ADAMTS-4 at 100 ng/ml compared to control micro-
glia, P = 0.0209), GDNF (Fig. 10l: −15.1 % for microglia
treated with ADAMTS-4 at 100 ng/ml compared to
(See figure on previous page.)
Fig. 8 rADAMTS-4 increases astrogliosis in the lumbar spinal cord of female SOD1G93A mice. a Representative photomicrographs of ventral horns
in lumbar spinal cord sections from WT and control or ADAMTS-4-treated SOD1G93A mice stained with GFAP. Scale bar: 250 μm. b Quantification
of GFAP immunoreactivity per area from male mice (a). Values plotted are mean ± SEM. Two-way ANOVA: ***P < 0.001 WT Vs SOD1G93A. Unpaired
two-tailed t-Test: P > 0.05 Control Vs ADAMTS-4 SOD1G93A, N = 3 Control WT, N = 5 ADAMTS-4 WT, N = 8 Control SOD1G93A, N = 7 ADAMTS-4
SOD1G93A. c Quantification of GFAP immunoreactivity per area from female mice (a). Values plotted are mean ± SEM. Two-way ANOVA: ***P < 0.001 WT Vs
SOD1G93A. Unpaired two-tailed t-Test: $P < 0.05 Control Vs ADAMTS-4 SOD1G93A, N= 5 Control WT, N= 3 ADAMTS-4 WT, N= 5 Control SOD1G93A, N= 6
ADAMTS-4 SOD1G93A. d Representative photomicrographs of ventral horns in lumbar spinal cord sections from WT and control or ADAMTS-4-treated
SOD1G93A mice stained with Iba1. Scale bar: 250 μm. e Quantification of Iba1 immunoreactivity per area from male mice (d). Values plotted are mean ±
SEM. Two-way ANOVA: ***P < 0.001 WT Vs SOD1G93A. Unpaired two-tailed t-Test: P > 0.05 Control Vs ADAMTS-4 SOD1G93A, N= 3 Control WT, N= 5
ADAMTS-4 WT, N = 8 Control SOD1G93A, N = 7 ADAMTS-4 SOD1G93A. f Quantification of Iba1 immunoreactivity per area from female mice
(d). Values plotted are mean ± SEM. Two-way ANOVA: ***P < 0.001 WT Vs SOD1G93A. Unpaired two-tailed t-Test: P > 0.05 Control Vs ADAMTS-4 SOD1G93A,
N= 5 Control WT, N= 3 ADAMTS-4 WT, N= 5 Control SOD1G93A, N= 6 ADAMTS-4 SOD1G93A
Fig. 9 rADAMTS-4 is not toxic to cortical neurons in vitro. Neuronal viability assessed by MTT assay in primary cortical neuron cultures treated or
not with a human recombinant ADAMTS-4 (a-b) or ADAMTS-1 (c-d) at different doses (20, 100, 200, 500 ng/ml) 30 min before exposure (b, d) or
not (a, c) to glutamate 400 μM (Glu) during 24 h. Values plotted are mean ± SEM. Mann–Whitney U-tests: P > 0.05 control Vs ADAMTS, ***P < 0.001
control Vs glutamate, P > 0.05 glutamate Vs glutamate + ADAMTS, N = 11-12 from 3 independent experiments
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control microglia, P = 0.0209) and BDNF (Fig. 10m:
−22.4 % or −18.9 % for microglia treated with
ADAMTS-4 at 100 or 200 ng/ml compared to control
microglia, P = 0.0209) in microglia cultures. ELISA failed
to detect NGF in microglia culture media (data not
shown). ADAMTS-4 was not toxic to cultured
microglia.
To confirm these results, we transfected microglial
cells for 2 h with silencing siRNAs targeting ADAMTS-
4 or with an empty vector (mock) as a control. After
48 h, ADAMTS-4 gene expression was decreased by
68 % in microglial cells transfected with siRNAs silen-
cing ADAMTS-4 expression compared to control micro-
glia (Fig. 10n: P = 0.0008). Importantly, we observed an
increase in the mRNA levels of NGF (Fig. 10o: +25.1 %
for microglia transfected with siRNAs targeting
ADAMTS-4 compared to control microglia, P = 0.0117),
GDNF (Fig. 10p: +30.7 % for microglia transfected with
siRNAs targeting ADAMTS-4 compared to control
microglia, P = 0.0008) and BDNF (Fig. 10q: +44.2 % for
microglia transfected with siRNAs targeting ADAMTS-4
compared to control microglia, P = 0.0117) in microglial
cells transfected with siRNAs silencing ADAMTS-4 ex-
pression compared to control microglia.
ADAMTS-4 treatment decreases NGF expression in the
ventral horn of the lumbar spinal cord of male SOD1G93A
mice
We next aimed to determine whether the regulation of
neurotrophic factor expression and release by
ADAMTS-4 evidenced in vitro (Fig. 10) may contribute
at least partly to the deleterious effects of ADAMTS-4
observed in vivo in SOD1G93A mice. For that purpose,
we immunostained NGF in lumbar spinal cord sections
of SOD1G93A mice treated or not with ADAMTS-4.
Interestingly, we observed a 2-fold decrease of NGF ex-
pression in the ventral horn of the lumbar spinal cords
of SOD1G93A male mice treated with ADAMTS-4 com-
pared to untreated SOD1G93A mice (Fig. 11a-b: −54.9 %
for ADAMTS-4-treated SOD1G93A mice compared to
untreated SOD1G93A mice, P = 0.0209). However, no dif-
ference of NGF expression was found between
SOD1G93A female mice treated or not with ADAMTS-4
(Fig. 11c-d: P = 0.9907).
Discussion
ADAMTS-4 is a metalloproteinase specialized in the
degradation of chondroitin sulfate proteoglycans
(CSPGs) whose functions during neurodegenerative dis-
eases, including ALS, have not been investigated. Here,
we demonstrated that (i) ADAMTS-4 activity is de-
creased at disease end-stage in the spinal cord of
SOD1G93A mice, and that (ii) provision of exogenous
ADAMTS-4 promoted the degradation of perineuronal
nets (PNNs) and decreased glial production of neu-
rotrophic factors, possibly thereby enhancing neuro-
degeneration and subsequent motor impairments in
SOD1G93A mice (Fig. 12a).
In contrast to other ADAMTS proteoglycanases,
ADAMTS-4 is highly expressed in the CNS in all types
of cells [1, 20–23]. However, ADAMTS proteoglyca-
nases display different potency for CSPGs. For ex-
ample, ADAMTS-5 is more potent than ADAMTS-4
for the proteolysis of aggrecan [24, 25], a CSPG found
exclusively in PNNs. Nevertheless, ADAMTS functions
extend beyond proteolysis by regulating synaptic pro-
tein expression (ADAMTS-1) [3] or neurotrophic fac-
tor expression/release (ADAMTS-4). Modifications of
ADAMTS-4 expression/activity have been reported
during spinal cord injury (SCI), experimental auto-
immune encephalomyelitis and multiple sclerosis [1].
Here, we showed that ADAMTS-4 activity was de-
creased in the lumbar spinal cord of SOD1G93A mice
compared to WT mice at disease end-stage. This re-
duction could be related to a myriad of events, includ-
ing a decrease of ADAMTS-4 gene/protein expression,
an increase of the proteolytic cleavage of ADAMTS-4
mature form, and an increase of its inhibitor TIMP-3.
(See figure on previous page.)
Fig. 10 ADAMTS-4 modulates the synthesis/release of neurotrophic factors by glial cells in vitro. a-c Quantitative RT-PCR for NGF (a) GDNF (b)
and BDNF (c) expression in mouse adult cortical astrocyte cultures treated or not for 48 h with a human recombinant ADAMTS-4 (20, 100,
200 ng/ml). Values plotted are mean ± SEM. Mann–Whitney U-tests: *P < 0.05 compared to control, N = 4. d-e ELISA-measurements of NGF
released in the media of mouse adult cortical astrocyte cultures treated or not for 48 h with a human recombinant ADAMTS-4 (d) or ADAMTS-1
(e) at different doses (20, 100, 200 ng/ml). Values plotted are mean ± SEM. Mann–Whitney U-tests: *P < 0.05 (ADAMTS-4) or P > 0.05 (ADAMTS-1)
compared to control, N = 3. f-i Quantitative RT-PCR for ADAMTS-4 (f) NGF (g) GDNF (h) and BDNF (i) expression in mouse adult cortical astrocyte
cultures transfected or not for 48 h with empty vector (mock) or silencing RNAs (siRNAs) targeting the expression of ADAMTS-4. Values plotted
are mean ± SEM. Mann–Whitney U-tests: *P < 0.05 (ADAMTS-4, NGF, GDNF) or P > 0.05 (BDNF) compared to mock, N = 4. j ELISA-measurements of
NGF released in the media of mouse adult cortical astrocyte cultures transfected or not for 48 h with mock or siRNAs targeting the expression of
ADAMTS-4. Values plotted are mean ± SEM. Mann–Whitney U-tests: *P < 0.05 compared to control, N = 4. k-m Quantitative RT-PCR for NGF (k)
GDNF (l) and BDNF (m) expression in mouse neonatal cerebral microglia cultures treated or not for 48 h with a human recombinant ADAMTS-4
(20, 100, 200 ng/ml). Values plotted are mean ± SEM. Mann–Whitney U-tests: *P < 0.05 compared to control, N = 4. n-q Quantitative RT-PCR for
ADAMTS-4 (n) NGF (o) GDNF (p) and BDNF (q) expression in mouse neonatal cerebral microglia cultures transfected or not for 48 h with mock or
siRNAs targeting the expression of ADAMTS-4. Values plotted are mean ± SEM. Mann–Whitney U-tests: *P < 0.05 (NGF, BDNF), ***P < 0.001
(ADAMTS-4, GDNF) compared to mock, N = 8
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TIMP-3 is also an inhibitor for ADAMTS-1 and −5,
which may impair their activities although their ex-
pressions are increased in the lumbar spinal cord of
SOD1G93A mice.
We and others have previously shown that exogenous
supply of ADAMTS-4 after SCI in rats promotes neuro-
plasticity by degrading CSPGs and subsequent functional
recovery [5, 6]. One possible reason why ADAMTS-4 is
beneficial after SCI while it is deleterious during ALS
may rely on the impact of CSPGs/PNNs degradation in
these two diseases. Indeed, while it is clear that CSPGs
are highly induced after SCI and represent strong inhibi-
tors for neuroregeneration in this context, their expres-
sion and role during neurodegenerative diseases
including ALS are poorly understood [18, 26–28].
Nevertheless, increasing evidence shows that the neu-
rons devoid of a net are less protected against neurode-
generation compared to PNNs-bearing neurons in
Alzheimer disease (AD) or oxidative stress animal
models [29–31]. Forostyak and colleagues have shown
that the PNNs enwrapping spinal motoneurons of
SOD1G93A rats are considerably degraded at disease
end-stage compared to WT rats. Additionally, they
showed that PNNs are partly preserved in SOD1G93A
rats after transplantation of bone marrow mesenchymal
stromal cells and that this effect is associated with an in-
crease of motoneuron survival and an increase of
SOD1G93A rats survival [18]. Similarly, we showed here a
decrease of PNNs around motoneurons of the lumbar
spinal cord of SOD1G93A mice at the symptomatic stage.
Disorganized SOD1G93A-PNNs may facilitate local deg-
radation of the remaining aggrecan by ADAMTS-4 since
PNNs were even more damaged in ADAMTS-4-treated
SOD1G93A mice. This was associated with an increased
neurodegeneration and a poor functional outcome. Our
results suggest that digestion of PNNs by ADAMTS-4
may be harmful for motoneurons during ALS pathology.
Because PNNs only contain 2 % of total CSPGs [32], we
cannot exclude that ADAMTS-4 may have an effect on
digestion of the 98 % remaining CSPGs.
Neurotrophic factors have been extensively described
to protect dying motoneurons and represent a potential
therapeutic strategy in ALS [33, 34]. Here we described
for the first time that ADAMTS-4 decreased the expres-
sion of several neurotrophic factors in astrocytes and
microglia. Accordingly, decreasing ADAMTS-4 expres-
sion by siRNA approach led to an increase of neu-
rotrophic factor expression. This demonstrates that
Fig. 11 rADAMTS-4 decreases NGF expression in the lumbar spinal cord of male SOD1G93A mice. a Representative photomicrographs of ventral
horns in lumbar spinal cord sections from control or ADAMTS-4-treated SOD1G93A male mice stained with NGF. Scale bar: 125 μm. b Quantification of NGF
immunoreactivity per area from male mice (a). Values plotted are mean ± SEM. Unpaired two-tailed t-Test: $P < 0.05 Control Vs ADAMTS-4 SOD1G93A, N= 8
Control SOD1G93A, N= 7 ADAMTS-4 SOD1G93A. c Representative photomicrographs of ventral horns in lumbar spinal cord sections from control or
ADAMTS-4-treated SOD1G93A female mice stained with NGF. Scale bar: 125 μm. d Quantification of NGF immunoreactivity per area from female mice (c).
Values plotted are mean ± SEM. Unpaired two-tailed t-Test: P > 0.05 Control Vs ADAMTS-4 SOD1G93A, N= 5 Control SOD1G93A, N= 6 ADAMTS-4 SOD1G93A
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ADAMTS-4 functions are not limited only to CSPGs
degradation. It would be interesting to determine
whether ADAMTS-4 may induce mechanisms previ-
ously described to downregulate neurotrophic factor
production, for instance, by modulating the nuclear
translocation of transcription factors such as the histone
deacetylase HDAC6 (negative regulator) [35], CREB
(cAMP response element-binding protein) or NF-κB
(nuclear factor kappa B) (positive regulators) [36–38],
and/or by modulating micro-RNAs (miR) production
such as miR-15a, miR-132, miR-134, miR-221 or Let-7
miR [39–41]. Because ADAMTS-4 did not increase
glutamate-induced neuronal death in vitro, we
hypothesize that ADAMTS-4-dependent decrease of
neurotrophic factors released by glial cells around dying
motoneurons during ALS may participate in the acceler-
ated neurodegeneration induced by ADAMTS-4 in vivo.
The neurotrophic factor production after ADAMTS-4
treatment has not been studied in SCI studies so far, but
we could hypothesize that even if ADAMTS-4 also in-
duced a decrease of neurotrophic factor production in
the context of SCI, its impact may be negligible com-
pared to the great benefit of the CSPGs/PNNs
degradation-induced neuroregeneration [5, 6]. Among
the neurotrophic factors modulated by ADAMTS-4,
NGF is of particular interest as it exerts dual roles on
neuronal survival/cell death depending on whether it ac-
tivates the tyrosine kinase receptor TrkA or the tumor
Fig. 12 Gender similarities and differences in the effect of ADAMTS-4 treatment on ALS. a Schematic representation of ADAMTS-4 treatment
promoting the decline of NGF production and ALS-induced perineuronal net degradation which contribute to the degeneration and even death
of motoneurons in the ventral horn of the lumbar spinal cord of SOD1G93A mice. b A table describing the similarities and differences observed in
behavioral and anatomical effects of ADAMTS-4 treatment in SOD1G93A male and female mice
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necrosis factor receptor p75NTR [42], two receptors in-
duced after injury and in ALS [43, 44]. Although
astrocyte-derived NGF was described to promote moto-
neuron cell death through the activation of p75NTR re-
ceptor during ALS [45, 46], it was also described that
the surviving motoneurons expressed the TrkA receptor
[43], suggesting that NGF-TrkA signaling also plays a
critical role in the survival of motoneurons. Additionally,
NGF-p75NTR signaling reduces astrocyte proliferation in
vitro and in vivo in an autocrine manner [47].
ADAMTS-4-mediated reduction in NGF release by
astrocytes may contribute to neurodegeneration in
ADAMTS-4-treated SOD1G93A mice by preventing
TrkA signaling in surviving motoneurons. The decrease
of astrocytic NGF-p75NTR signaling could also explain
the increase in astrocyte activation/proliferation ob-
served in ADAMTS-4-treated SOD1G93A females.
Contrary to ADAMTS-4-treated SOD1G93A males, no
modification of NGF expression was identified in the
lumbar spinal cords of ADAMTS-4-treated SOD1G93A
females. Nevertheless, we cannot rule out that: i) the de-
crease of NGF in ADAMTS-4-treated SOD1G93A fe-
males may have occurred earlier than the time point
studied here. ii) the main source of NGF is provided by
astrocytes, therefore the increased astrogliosis observed
in the lumbar spinal cord of ADAMTS-4-treated
SOD1G93A females might mask the reducing effect of
ADAMTS-4 on NGF astrocytic expression.
This study reveals intriguing gender-specific effects of
ADAMTS-4 at the functional and anatomical levels
(Fig. 12b). While ADAMTS-4-treated SOD1G93A males
presented clinical signs of neuromuscular dysfunctions
20 days earlier than untreated SOD1G93A males,
ADAMTS-4-treated SOD1G93A females had symptoms
of neuromuscular dysfunctions at the same age as un-
treated SOD1G93A females. Even though we evidenced
that the motor performance of ADAMTS-4-treated
SOD1G93A females was more impaired than untreated
SOD1G93A females at symptom onset, it is clear that
ADAMTS-4 more severely impaired the functional out-
come of SOD1G93A males than females. Surprisingly, this
does not reflect what happened at the anatomical level,
since ADAMTS-4 caused motoneuron death in
SOD1G93A females and only mild motoneuron degener-
ation in SOD1G93A males. It is difficult to explain such
non-linear relationship between functional and anatom-
ical outcomes in ADAMTS-4-treated SOD1G93A males
(severe functional impairment/mild neurodegeneration)
or females (mild functional impairment/severe neurode-
generation). However, the fact that motoneuron degen-
eration obviously led to cell death in ADAMTS-4-
treated SOD1G93A females but not yet in males may be
due to the increased astrogliosis induced by ADAMTS-4
in SOD1G93A females, but not in males. Estrogens may
most likely play a role in some of the mechanisms medi-
ated by ADAMTS-4. Gender-specific effects of another
ADAMTS proteoglycanase, ADAMTS-1, have been pre-
viously observed in the CNS where a decline of synaptic
proteins was evidenced in the frontal cortex of
ADAMTS-1 knock-out female mice during develop-
ment, but not in males [3].
Conclusions
To conclude, our results provide the first evidence that
ADAMTS-4 promotes neurodegeneration in the context
of ALS. It would be interesting to determine if: (i) en-
dogenous ADAMTS-4 contributes to neurodegeneration
in mice expressing high copy number of mutant SOD1
as well as in other model of ALS such as WT or mutant
TDP43 (TAR DNA-binding protein 43) rodent models,
or even in frontotemporal dementia or AD models; (ii)
therapeutic approaches aimed at decreasing ADAMTS-4
expression/activity would represent potential targets to
slow down neurodegeneration in chronic CNS diseases.
Methods
Ethics
Animal experiments were conducted according to the
national regulation of the usage and welfare of labora-
tory animals, approved by the National Animal Experi-
ment Board of Finland and followed the Council of
Europe legislation and regulation for animal protection.
Animals
Transgenic male and female mice over-expressing the
human superoxide dismutase SOD1G93A mutation were
also purchased from the Jackson laboratory (Bar Harbor,
Maine, USA) and maintained on C57BL/6 J congenic
background. Transgenic genotypes were identified by
polymerase chain reaction (PCR) amplification of ear
DNA a few days after birth and of liver DNA after death
to confirm the results of the first genotyping. PCR re-
vealed a low copy number of mutated SOD1 in the mice
used in this study. The mice were housed under con-
trolled temperature, humidity and light conditions (12 h
light and dark cycles) with free access to food and water.
Animals of the same sex were housed in groups of up to
5 in cages. WT and SOD1G93A mice were used for the 2
studies described hereafter.
Study 1: ADAMTS-4 expression in the time course of ALS
– Characterization of the disease stage in
SOD1G93Amice. Male and female SOD1G93A mice
and WT littermates from generations 18–19 were
sacrificed at key time points during the development
of the ALS pathology: presymptomatic (m/f: ~13/
14.5 weeks-old), symptomatic (m/f: ~20.5/22 weeks-
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old) and end-stages (m/f: ~27/28 weeks-old). The
symptomatic stage was estimated based on the
symptom onset of SOD1G93A mice from the previous
cohort, and confirmed when the mice developed
abnormal hindlimb splay reflexes when suspended by
their tails. The end-stage was defined as the age when
the mice suffered from functional paralysis of the
hindlimbs. At disease end-stage, SOD1G93A mice were
given macerated food for easier food uptake and
hydration. Mice were sacrificed by terminal perfusion
with heparinized saline, followed or not by paraformal-
dehyde (PFA) perfusion (as described in the immuno-
histochemistry section) for respectively RNA (N = 3-4
in each group)/protein (N = 4 in each group) (cortices,
cervical, thoracic and lumbar spinal cords) or staining
(N = 3 in each group) (lumbar spinal cords) purposes.
Study 2: ADAMTS-4 treatment and functional outcome in
ALS
– Intracerebroventricular injection of recombinant
ADAMTS-4. Male and female WT and SOD1G93A
mice from generations 20–22 were randomized into
treatment groups using GraphPad Quickcalcs
(GraphPad Software Inc., La Jolla, CA, USA): N = 5
Control WT males, N = 5 ADAMTS-4 WT males,
N = 9 Control SOD1G93A males, N = 9 ADAMTS-4
SOD1G93A males, N = 5 Control WT females, N = 4
ADAMTS-4 WT females, N = 7 Control SOD1G93A
females, N = 6 ADAMTS-4 SOD1G93A females. The
anesthesia of mice was induced by 5 % isoflurane in
a 70 %/30 % mixture of NO2/O2 and maintained at
2 % isoflurane during the surgery. The temperature
of the mice was controlled by a homeothermic con-
trol system connected to a heating blanket and rec-
tal probe (Harvard apparatus, Pan Lab, Barcelona,
Spain). A 4-μl volume containing saline or 40 ng of
a human recombinant ADAMTS-4 (CC1028, Merck
Millipore, Darmstadt, Germany) was injected bilat-
erally into lateral ventricles using a 5-μl Hamilton
syringe (Hamilton company, Reno, Nevada, USA) at
the age of 9 and 13 weeks (coordinates from
Bregma: mediolateral = ± 1 mm, anteroposterior = −
0.5 mm, dorsoventral = − 3 mm).
– Assessment of functional outcome. Disease onset was
determined by the wire hang test [48]. Each mouse
was placed on a wire lid of a conventional cage
which was turned upside down and the latency of
the mouse to fall was recorded. Deficits in motor
performance were defined by the inability to hang
for more than 3 min. If the mouse fell, the test was
repeated for the second time. The test was
performed 3 times a week. In parallel, the weight of
the transgenic mice was recorded 3 times a week
using a normal digital balance, while WT mice were
only weighted once a week. The testing was
performed blinded to the experimental groups. Mice
were sacrificed during the symptomatic stage (m/f:
~29/35 weeks-old) by terminal perfusion with
heparinized saline, followed by PFA perfusion (as
described in the immunohistochemistry section) for
staining (lumbar spinal cords) purposes.
Quantitative real-time PCR
Total RNAs were isolated by homogenizing spinal
cords or cortex in TRIzol (Life technologies, Carlsbad,
CA, USA) according to manufacturer’s instructions
utilizing 5-mm stainless steel beads and a Tissuelyzer
II homogenizator (Qiagen, Leusden, NL, USA). Total
RNAs from cells were isolated with the RNeasy Mini
Kit (Qiagen). Synthesis of cDNA was performed by
using 500 ng of total RNA, Maxima reverse transcript-
ase, dNTP and random hexamer primers (Life tech-
nologies). The final concentration of cDNA was
2.5 ng/μl. The relative expression levels of mRNAs en-
coding the selected genes were run in duplicates and
measured according to the manufacturer’s protocol by
quantitative RT-PCR (StepOne Plus™ Real-Time PCR
system; Life technologies) and using specific assays-
on-demand target mixes (Life technologies) as follows:
ADAMTS-1: Mm00477355_m1; ADAMTS4: Mm005
56068_m1; ADAMTS-5: Mm00478620_m1; ADAM
TS-9: Mm00614433_m1; TIMP-3 (type 3 tissue inhibi-
tor of metalloproteinases): Mm00441826_m1; Aggrecan:
Mm00545794_m1; BDNF (brain-derived neurotrophic
factor): Mm0133402_m1; NGF (nerve growth factor):
Mm00443039_m1; GDNF (glial cell-derived neurotrophic
factor): Mm00599849_m1; HAPLN1 (hyaluronan and pro-
teoglycan link protein 1): Mm00488952_m1; Tenascin R:
Mm00659075_m1; GAPDH (glyceraldehyde-3-phosphate
dehydrogenase): 4352932E (Applied Biosystems, Warring-
ton, UK). The expression levels were normalized to
GAPDH. Relative mRNA transcription was expressed as a
percentage of control conditions using the 2─ΔΔCt method
where Ct is the threshold-cycle value. The relative ex-
pression of ADAMTS proteoglycanases was expressed
as a percentage of ADAMTS-1 gene expression using
the 2─ΔΔCt method: 2-((ΔCt ADAMTS-1 - ΔCt GAPDH) -
(ΔCt ADAMTS-4, 5 or 9 - ΔCt GAPDH)).
Protein extraction
Cortices as well as cervical, thoracic or lumbar spinal cords
were dissociated in ice-cold TNT buffer (50 mM Tris–HCl
pH 7.4; 150 mM NaCl; 0.5 % Triton X-100) containing
EDTA/EGTA (ethylene diamine/glycol tetraacetic acid,
1 mM), protease (Sigma-Aldrich, St Louis, MO, USA) and
phosphatase (Roche Diagnostics, Mannheim, Germany)
inhibitors. For the ADAMTS-4 fluorimetric assay, lumbar
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spinal cords were dissociated in TNT buffer without prote-
ase and phosphatase inhibitors. Debris were removed by
centrifugation (12,000 g at 4 °C, 15 min). Supernatants were
stored at −70 °C until further processing. Protein quantifi-
cation was performed according to the BCA protein
method (Pierce, Rockford, USA).
Western blot
Proteins (5 μg) were resolved on 12 % polyacrylamide
gel under denaturing conditions and transferred onto a
polyvinylidene difluoride membrane. Membranes were
blocked with phosphate buffered saline (PBS) tween
(0.2 % Tween-20; Sigma-Aldrich) and 5 % of milk. Blots
were incubated overnight at 4 °C with the rabbit anti-
ADAMTS-4 (1/5000; AbCam, Cambridge, UK) or the
rabbit anti-ADAMTS-5 (1/1000; AbCam) primary anti-
bodies diluted in PBS-tween containing 5 % of bovine al-
bumin serum (BSA). After a 2-h incubation at room
temperature (RT) with the peroxidase-conjugated anti-
rabbit secondary antibody (1/2000; GE Healthcare life
sciences, Uppsala, Sweden), proteins were revealed with
an enhanced chemiluminescence ECL-Plus kit immuno-
blotting detection system (GE Healthcare life sciences)
and visualized using StormTM FluorImager system.
Mouse anti-β-actin (1/5000; Sigma-Aldrich) was used as
a loading control and visualized by Alexa fluor 647-
conjugated anti-mouse secondary antibody (1/1000;
Jackson ImmunoResearch laboratories Inc., West Grove,
PA, USA).
Ex vivo CSPG proteolysis by ADAMTS human
recombinant proteins
Sixteen μg of lumbar spinal cord protein extracts from
symptomatic SOD1G93A male mice were exposed or
not to 1 μg of human recombinant ADAMTS-1 (2197-
AD-020), ADAMTS-4 (4307-AD-020) or ADAMTS-5
(2198-AD-020; all recombinant proteins were from
R&D SYSTEMS, Minneapolis, MN, USA) in the aggre-
canase buffer (50 mM TrisHCl, 125 mM NaCl, 5 mM
CaCl2, pH 7.5) within a final volume of 55 μl, for 24 h
at 37 °C (N = 4 per condition). The reaction was
stopped by heating the samples at 75 °C for 10 min.
Twelve μl of each condition of the above preparations
were resolved in a 6 % polyacrylamide gel, the membrane
probed with the mouse anti-CSPG antibody (1/1000;
Sigma-Aldrich), then with the peroxidase-conjugated anti-
mouse secondary antibody (1/5000; GE Healthcare life
sciences) and finally revealed by ECL detection, as previ-
ously described in the Western Blot section.
Fluorimetric assay for ADAMTS-4
A fluorogenic substrate (5-FAM/TAMRA; SensoLyte®
520 Aggrecanase-1 assay kit, Eurogentec, San Jose, CA)
was incubated with protein extracts of lumbar spinal
cords (25 μg in 50 μl) of WT and SOD1G93A male and
female mice at presymptomatic, symptomatic and end-
stages (N = 4 in each group). Measurements were per-
formed at 37 °C over 60 min using a multiplate reader.
The slope of each absorbance curve was then deter-
mined between 10 and 20 min.
Immunohistochemistry
Anesthetized mice were perfused with cold heparinized
saline and, thereafter, with a solution containing 4 %
PFA in 0.1 M phosphate buffer (PB) pH 7.4. Lumbar
spinal cords were removed and rinsed in a PB containing
20 % sucrose for cryoprotection for 24 h. The spinal
cords were embedded and frozen in OCT (Optimal Cutting
Temperature; Sakura Finetek, Tokyo, Japan). Five 12-μm-
transverse sections 200 μm apart covering a 1-mm-length
of each lumbar spinal cord were cut on a cryostat, collected
on lysine glasses (Thermo Scientific, UK), and stored
at −70 °C until analysis. After washing with PB, PBS
and PBS-tween (0.05 % Tween-20), sections were
treated as required with PBS-TritonX-100 (0.4 %,
Sigma-Aldrich) and unspecific binding was blocked
with 1 h incubation with 10 % normal goat or rabbit serum
(NGS or NRS; Vector Laboratories Ltd, Burlingame, CA)
or 0.5 % mouse on mouse reagent (MOM; Vector Labora-
tories Ltd). Incubation with primary antibodies was con-
ducted overnight at RT with dilutions as follows: rabbit
anti-ADAMTS-4 (1/500; AbCam), rabbit anti-GFAP (glial
fibrillary acidic protein, 1/200; Dako, Glostrup, Denmark),
mouse anti-GFAP (1/400; Merck Millipore), rabbit anti-
Iba1 (ionized calcium-binding adapter molecule-1, 1/250;
Wako Pure Chemical Industries, Ltd, Tokyo, Japan), mouse
anti-NeuN (1/200; Chemicon, Billerica, MA, USA), rabbit
anti-NGF (1/100; AbCam), mouse anti-APC (Adenomatous
polyposis coli, 1/200; Merck Millipore) or lectin from
Wisteria Floribunda (WFA, Wisteria Floribunda Agglutin,
1/1000; Sigma-Aldrich). After washing with PBS-tween,
sections were incubated with corresponding fluorescent
Alexa fluor −488 or −568-conjugated secondary antibodies
(1/200; Life technologies) or with a fluorescent Alexa fluor-
568 secondary antibody conjugated to streptavidin (for
WFA staining, 1/500; Life technologies) for 2 h at RT, then
washed again and finally mounted in Vectashield with
DAPI (Vector Laboratories Ltd). For choline acetyltransfer-
ase (ChAT) staining, sections were incubated in 0.3 %
H2O2 diluted in MeOH for 30 min to block endogenous
peroxidase activity followed by heat-mediated antigen re-
trieval for 30 min in 0.05 M citrate buffer, pH 6.0. After
blocking unspecific binding, sections were incubated
in primary antibody (1/500; Chemicon), followed on
the next day by 1-h incubation in biotinylated second-
ary antibody (1/200) and then incubation in avidin-
biotin complex solution (Vectastain Elite kit, both
from Vector Laboratories Inc., USA). The staining was
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visualized using nickel-enhanced diaminobenzidine
(Sigma-Aldrich) with 0.075 % H2O2 as chromogen/
substrate reagent solution. Negative controls for un-
specific binding of the secondary antibodies were con-
ducted in parallel sections following the same
procedures described above except the incubation in
primary antibodies.
For GFAP, Iba1, WFA, ChAT and NGF analyses, the ven-
tral horn of the lumbar spinal cords were imaged using 10x
(GFAP, Iba1, ChAT), 20x (WFA) or 40x (NGF) magnifica-
tion on an AX70 microscope (Olympus corporation, Tokyo,
Japan) coupled to a digital camera (Color View 12, soft Im-
aging System, Muenster, Germany) using Soft Imaging soft-
ware: N = 3 Control WT males, N = 5 ADAMTS-4 WT
males, N = 8 Control SOD1G93A males, N = 7 ADAMTS-4
SOD1G93A males, N = 5 Control WT females, N = 3
ADAMTS-4 WT females, N = 5 Control SOD1G93A fe-
males, N = 6 ADAMTS-4 SOD1G93A females. Immunoreac-
tivity for GFAP, Iba1, WFA or NGF were quantified using
Image-Pro Plus software (Media Cybernetics, Rockville,
MO, USA) at a pre-defined range, measured as the relative
immunoreactive area for GFAP, Iba1, WFA or NGF. The
number and size of ChAT-positive motoneurons were mea-
sured by using Image-Pro Premier software (Media Cyber-
netics). Co-localization of NeuN, GFAP or APC with
ADAMTS-4 were assessed by a Zeiss LSM 700 confocal
microscope coupled to a digital camera using Zen 2009
Image Analysis Software (Zeiss Inc., Maple Grove, USA).
Primary neuron culture
Primary neuron cultures were prepared as described pre-
viously [49]. Cortices were isolated from 14 day-old
mouse embryos in sterile Krebs solution containing
125 mM NaCl, 5 mM KCl, 1 mM NaH2PO4, 15 mM D-
glucose, 25 mM HEPES, 0.05 mM BSA and 2 mM
MgSO4. Cortices were then incubated for 15 min at 37 °C
in Krebs solution containing 0.1 mM trypsin (Sigma-
Aldrich). Krebs solution containing 25 nM DNAse
(Sigma-Aldrich) and 130 nM soy bean trypsin inhibi-
tor (Sigma-Aldrich) was added to the suspension (1:1
dilution), and then centrifuged at 250 g for 3 min. The
pellet was resuspended in new Krebs solution, and
centrifuged again. The cells were finally resuspended
in Neurobasal medium supplemented with 2 % B-27
supplement and 0.5 mM L-glutamine. Neurons were
plated on 48 well-plates at a density of 125 000 cells/
well previously coated with 5 μg/ml poly-D-lysine and
were used for experiments 6 days after plating. After
5 days, half of the medium was changed to complete
Neurobasal medium.
Treatment of neurons with recombinant proteins
Cultured neurons were treated with either a human re-
combinant ADAMTS-1 (2197-AD-020) or a human
recombinant ADAMTS-4 (4307-AD-020; R&D SYSTEMS)
at 20, 100, 200 or 500 ng/ml 30 min before exposure or not
to 400 μM glutamate (Sigma-Aldrich) (N = 11-12 from 3
independent experiments).
MTT assay
After 24 h’ exposure to glutamate, the neuron viability
was assessed by measuring 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide reduction (MTT;
Sigma-Aldrich). For that purpose, cells were incubated
with 120 μM MTT for 1 h before lysing in dimethyl sulf-
oxide (DMSO; J.T.Baker, Deventer, The Netherlands)
and quantifying absorbance at 540 nm.
Adult astrocyte culture
Primary cortical astrocyte cultures were prepared as de-
scribed previously [50] with some modifications. Briefly,
cortices were isolated from 6–8 week-old C57Bl/6 J mice
and the tissue was suspended in Hank’s Balanced Salt
Solution (HBSS, GIBCO, Life technologies) and centri-
fuged at 400 g for 5 min at RT. After the addition of
0.25 % trypsin-EDTA (GIBCO, Life technologies), the
suspension was incubated at 37 °C for 30 min with occa-
sional shaking. Fresh culture medium containing serum
was added to neutralize the effect of trypsin and the sus-
pension was centrifuged at 400 g for 5 min. The cells
were treated with Percoll (Sigma-Aldrich) and centri-
fuged at 400 g for 10 min to separate the phases. The
supernatant was discarded and the layer of glial cells was
washed once with fresh culture media. The cells were
plated onto poly-L-lysine coated flasks in Dulbecco’s
Modified Eagle Medium Nutrient Mixture F-12
(DMEM/F12, GIBCO, Life technologies) containing
10 % heat-inactivated fetal bovine serum (FBS, GIBCO,
Life technologies), 2 mM L-Glutamine (GIBCO, Life
technologies), 100 U/ml penicillin/streptomycin (P/S,
GIBCO, Life technologies) and G5 supplement (Invitro-
gen, Life technologies). The astrocytic culture contains
on average 99 % of GFAP-positive cells. The microglial
cells were removed by shaking at 200 g for 2 h prior to
the experiments. Astrocytes were plated on 12 well-
plates at a density of 50 000 cells/well and used for ex-
periments 3 days after plating.
Primary microglial culture
Primary microglial cultures were prepared as described
previously [51, 52]. Brains were isolated from neonatal
C57Bl/6 J mice (P1-2), washed in PBS containing 1 %
glucose and mechanically and enzymatically dissociated
using trypsin (TrypLE Express, GIBCO, Life technolo-
gies). The suspension was incubated at 37 °C for 20 min.
Fresh culture medium containing FBS was added to
neutralize the effect of trypsin. The suspension was
plated in 15 cm-petradish in DMEM-F12 Glutamax
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(GIBCO, Life technologies) containing 1 % P/S and 10 %
FBS (complete media). After 3 weeks, cells were shaken
at 200 g and then washed with PBS before addition of
0.08 % trypsin-EDTA for 45 min in order to peel off the
astrocytes. After removal of astrocytes, microglial cells
were washed with PBS and 0.25 % trypsin-EDTA was
added for 5 min. After neutralizing trypsin with
complete media, cells were dislodged and centrifuged at
400 g for 5 min. Cells were resuspended in complete
media. Microglia were plated on 24-well plates at a
density of 200 000 cells/well. After one day, cells were
placed in serum-free media and used for experiments 2
or 3 days after plating.
Treatment of astrocytes and microglia with recombinant
proteins
Cultured cortical astrocytes and neonatal microglia were
treated with either a human recombinant ADAMTS-4
(4307-AD-020) or a human recombinant ADAMTS-1
(2197-AD-020; R&D SYSTEMS) at 20, 100 or 200 ng/ml
for 48 h. The culture media were collected for ELISA as-
says (N = 3 in each group) and the RNAs (N = 4 in each
group) were isolated from the corresponding cell layers
for quantitative real-time PCR.
siRNA assays
Silencing small-interfering RNAs (siRNAs) targeting the
expression of ADAMTS-4 (Sigma-Aldrich) were transi-
ently transfected in cultured cerebral microglia or cor-
tical astrocytes with the lipofectamine 2000 reagent
(Invitrogen, Life technologies) using the protocol pro-
vided by the manufacturer. For each well of a 12 well-
plate, 2 μg of siRNA and 4 μl of lipofectamine were
added to astrocytes previously deprived of serum. For
each well of a 24 well-plate, 1 μg of siRNA and 2 μl of li-
pofectamine were added to microglial cells in serum-free
fresh media. After 2 h of transfection, astrocytes or
microglia were rinsed and fresh culture medium con-
taining FBS (astrocytes) or not (microglia) was added.
After 48 h, cells were rinsed with PBS and RNA/culture
media were collected as described above. ADAMTS-4
siRNA sequences used were: Mm01-00044319, 5′-CC
CAUAUCCUUGUACGGCA-3′ and 3′-UGCCGUACAA
GGAUAUGGG-5′. As a control, empty vector (mock)
was used (Mission siRNA Universal negative control #1,
Sigma-Aldrich). ADAMTS-4 gene expression was sig-
nificantly decreased by 69 % in astrocyte cultures (N = 4
in each group) and by 68 % in microglia cultures (N = 8
in each group) transfected with siRNA silencing
ADAMTS-4 compared to mock.
NGF ELISA
The NGF protein concentrations were measured in
astrocyte (N = 3 and 4 in each group for respectively
recombinant and siRNA experiments) or microglia (N = 4
and 5 in each group for respectively recombinant and
siRNA experiments) culture media using the ChemiKineTM
NGF sandwich ELISA (Merck Millipore) following the
manufacturer’s instructions.
Statistical analyses
The data are expressed as mean ± SEM. An alpha level
of P < 0.05 was used for determination of significance in
all statistical tests. Molecular and cellular statistical ana-
lyses were performed with the Statview software package
(v5.0). Kruskal-Wallis test was used for intergroup mul-
tiple comparisons. In significant cases, Mann–Whitney
U-test was applied as post hoc test. Behavior and immu-
nohistochemistry statistical analyses were performed
using GraphPad Prism 5 (GraphPad Software Inc.).
Kaplan-Meier survival analyses and log-rank test were
used to compare the symptom onset of untreated
SOD1G93A and ADAMTS-4-treated SOD1G93A mice.
Two-way ANOVA was used to compare anatomical dif-
ferences between genotypes. Unpaired two-tailed t-test
was used for multiple comparisons.
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